Investor Alert

London Markets Close in:

Oct. 23, 2015, 12:08 p.m. EDT

At a $749 a pop discount, Martin Shkreli's AIDS drug has a new rival

Imprimis Pharmaceuticals said it is offering customizable compounded alternatives to Turing Pharmaceuticals' high-priced Daraprim for as low as $99 for a 100-count bottle. Turing bought the U.S. rights to Daraprim in August and promptly increased the price of the drug from $13.50 per tablet to $750 per tablet, leading to backlash and headlines last month. Both Daraprim and Imprimis' alternative are prescribed for infections afflicting patients with compromised immune systems, including patients with HIV/AIDS, pregnant women and children. The price hike raised questions about how prescription drugs can cost so much. Imprimis is also creating a new program, Imprimis Cares, that aims to provide these compounded formulations to combat high-priced generic drugs. Imprimis Pharmaceuticals is down 20.4% for the year so far. The Nasdaq is down 1.9% for the same period.

Link to MarketWatch's Slice.